Status: Recruiting
A Dose-exploration Study of EDP167 in HoFH
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eddingpharm (Zhuhai) Co., Ltd.Updated: May 20, 2026Locations: 1
Eligibility criteria
Age ≥18 years old, male or female, and weight ≥40 kg. [+7]
Allergic to the drug in this study, its components or similar drugs. [+18]